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The aim of this study was to formulate and prepare compression-coated tablets for colonic release 
(CR-tablets), and to evaluate the bioavailability of ketoprofen following the administration of a single 
dose from mini-tablets with immediate release (IR-tablets) compared to CR-tablets. CR-tablets were 
prepared based on time-controlled hydroxypropylmethylcellulose K100M inner compression-coating 
and pH-sensitive Eudragit® L 30D-55 outer film-coating. The clinical bioavailability study consisted of 
two periods, in which two formulations were administered to 6 volunteers, according to a randomized 
cross-over design. The apparent cumulative absorption amount of ketoprofen was estimated by plasma 
profile deconvolution. CR-tablets were able to delay ketoprofen’s release. Compared to IR-tablets used 
as reference, for the CR-tablets the maximum plasma concentration (Cmax) was lower (4920.33±1626.71 
ng/mL vs. 9549.50±2156.12 ng/mL for IR-tablets) and the time needed to reach Cmax (tmax) was 5.33±1.63 
h for CR-tablets vs. 1.33±0.88 h for IR-tablets. In vitro-in vivo comparison of the apparent cumulative 
absorption amount of ketoprofen showed similar values for the two formulations. Therefore, the obtained 
pharmacokinetic parameters and the in vitro-in vivo comparison demonstrated the reliability of the 
developed pharmaceutical system and the fact that it is able to avoid the release of ketoprofen in the 
first part of the digestive tract.
Keywords: Colonic delivery. Compression-coated tablets. pH-Dependent release. Time-dependent 
release. In vitro-in vivo comparison.
INTRODUCTION
A particular type of pharmaceutical system for 
colonic release is the chronopharmaceutical system with 
pulsatile release. The use of pulsatile release systems 
may be advantageous for adapting the treatment to 
chronopharmacological needs (for example, in the 
treatment of cardiovascular diseases, asthma, arthritis, 
ulcers) (Biswas et al., 2015; Vonica, Tomuță, Leucuța, 
2011) or to target a drug to a specific site in the digestive 
tract, for example in the colon (Hashem et al., 2011; 
Veerareddy, Vemula, 2012). Chronotherapeutical systems 
include among them the compression-coated tablets. 
The drug core of compression-coated tablets is usually 
represented by a mini-tablet which offers the advantages 
of reduced size, regular shape and smooth surface, thus 
providing excellent support for coating with various 
polymers.
Compression-coated tablets as colonic release 
systems are usually obtained by coating the drug cores 
by compression-coating (Fukui, Miyamura, Kobayashi, 
2001a, 2001b; Fukui et al., 2001). Very few works were 
found to prepared colon delivery systems by double-
compression coating (Vemula, 2015) or by compression-
coating combined with film-coating (Fukui et al., 2000). 
The polymers in the coating layers are usually soluble or 
insoluble matrix-forming polymers, capable of controling 
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drug release by matrix dissolution or erosion (Biswas et 
al., 2015), polysaccharides which control drug release 
through their enzymatic degradation by the colonic 
microflora (Sinha et al., 2004) or enteric polymers, which 
are insoluble in acidic media, but dissolve in slightly acid 
to neutral pH environments (Fukui et al., 2000). The 
association of two or more approaches has shown superior 
results regarding colon-specific drug release, namely 
negligible drug release in the stomach and small intestine 
and considerable amount of drug released in the colon. 
Despite the fact that there are several studies regarding 
chronotherapeutical systems, there is little published 
information available on colon-specific double-coated 
tablets based on associating time-controlled and pH-
sensitive approaches. Therefore, the present study sought 
to prepare a new ketoprofen colon-specific compression-
coated tablet system based on the combination of time-
controlled and pH-controlled polymers.
Ketoprofen is a nonsteroidal anti-inflammatory 
drug (NSAID) indicated mainly for analgesic and 
antiinflammatory effect in the treatment of pain and 
rheumatic diseases, respectively (Shohin et al., 2011; 
Yiyun, Tongwen, Rongqinag, 2005). Ketoprofen is 
considered a good candidate for colon delivery due to 
the well known gastric side effects (Maestrelli et al., 
2008), as well as to provide the chronotherapy in the 
treatment of rheumatoid arthritis, a disease influenced by 
circadian rhythms (Maestrelli et al., 2015). Thus, there are 
several research works that studied the strategies of oral 
administration and colon-specific release of ketoprofen. 
It was included in various pharmaceutical systems, from 
microparticles (Maestrelli et al., 2008; Maestrelli et 
al., 2015) to solid dispersions (Kamada et al., 2002; Xi 
et al., 2005), mini-tablets (Gazzaniga et al., 1994) and 
microparticle-based tablets (El-Gibaly, 2002).
This study aimed at (I) developing a ketoprofen 
colonic drug delivery system, pH and time dependent, by 
double-coating: the first step was compression-coating of 
ketoprofen mini-tablet cores (IR-tablets) with a layer based 
on a matrix-forming polymer (HPMC) and the second step 
was film-coating of the compression-coated tablets with 
an enteric outer film based on EL55 (Eudragit® L 30D-55), 
a methacrylic polymer. One of the greatest challenges for 
formulation scientists is to succeed obtaining the desired 
in vivo release profile and site specificity for a formulation 
previously characterized in vitro. There is a need of in 
vivo studies, especially of studies conducted on humans, 
therefore other objectives of our work were to (II) study 
the pharmacokinetics of the system in healthy human 
volunteers, and to (III) compare the in vitro-in vivo release 
of ketoprofen.
MATERIAL AND METHODS
Material
Ketoprofen (SIMS, Italy), was used as model drug. 
Lactose monohydrate for direct compression - Ludipress 
(BASF, Germany); microcrystalline cellulose PH 102 
(Pharma, Germany); polyvinylpyrrolidone (PVP) K30 – 
Kollidon K30 (BASF, Germany); sodium starch glycolate 
(JRS Pharma, Germany); hydroxypropylmethylcellulose 
(HPMC) – Methocel K100M (Colorcon, UK); silicon 
dioxide - Aerosil 200 (Degussa, Germany); magnesium 
stearate (Merck, Germany); EL55 (Evonik, Germany); 
Opadry II Orange (Colorcon, UK). All other chemicals 
were of analytical grade.
Preparation of the colonic delivery system
Preparation of IR-tablets
IR-tablets were prepared by wet granulation. The 
formula is presented in Table I. The blend of ketoprofen, 
lactose and 75% sodium starch glycolate was granulated 
with an alcoholic solution of PVP K30 15%, then the 
granules were dried, sieved and evaluated in terms of flow 
and granulometric characteristics. Before compression, 
the difference of 25% sodium starch glycolate and the 
lubricants were added. The IR-tablets (weight 20 mg, 17.2 
mg ketoprofen/tablet) were prepared using an eccentric 
tablet press (Korsch EK0, Germany), equipped with a 3 
mm diameter concave punch. IR-tablets were evaluated 
for weight variation, desagregation, hardness, friability, 
content uniformity and percentage of drug release in 15 
min according to European Pharmacopoeia (PhEur) 8th 
edition methods.
Compression-coating with time-dependent layer
IR-tablets were coated by compression with a 
TABLE I – Composition of IR-tablets
Constituent mg/IR-tablet %
Ketoprofen 17.2 86.00
Lactose monohydrate DC 0.40 2.00
Sodium starch glycolate 1.40 7.00
Polyvinylpyrrolidone K30 0.40 2.00
Silicon dioxide 0.10 0.50
Magnesium stearate 0.30 1.50
Talc 0.20 1.00
Total 20.00 100.00
IR-tablets – mini-tablets with immediate release.
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powder mixture containing HPMC K100M as matrix-
forming polymer. The same eccentric tablet press was 
used, equipped with a 7 mm diameter concave punch. 
The core tablets were coated by compression with 220 
mg coating mixture (Table II). About 50% of the coating 
powder mixture was placed in the die cavity. The core 
tablet was then placed in the center of the die cavity, 
which was filled with the remainder of the coating powder 
mixture and was compressed around the core tablets. 
The final mass of the tablets was 240 mg. The prepared 
compression-coated ketoprofen tablets were tested for 
weight variation, hardness, and friability.
Film-coating with pH-dependent layer
The compression-coated tablets were subsequently 
film-coated in a coating pan with an enterosoluble 
polymer: EL55, obtaining the CR-tablets. Table III shows 
the coating formula of the compression-coated tablets and 
the working conditions of the coating process. CR-tablets 
are shown schematically in Figure 1. After the coating, the 
tablets were maintained in a stability chamber (Binder, 
Germany) for 15 h, at 40 oC and 20% relative humidity in 
order to stabilize the polymer film (curing). 
In vitro drug release study
Ketoprofen release from CR-tablets was assessed 
by dissolution testing using the PhEur dissolution tester, 
apparatus I (rotating basket) (Pharma Test PT-DT7, 
Pharma Test, Germany) at a rotation speed of 50 rpm 
and 500 mL of dissolution fluid at 37.0±0.5 °C. HCl 
0.1 N (pH 1.2) was used as dissolution medium for 2 h, 
followed by phosphate buffer (pH 6.8) for another 3 h, 
and finally, by phosphate buffer (pH 7.4) until the end of 
24 h in order to simulate the pH in different parts of the 
gastrointestinal tract (Crcarevska, Dodov, Goracinova, 
2008; Meissner et al., 2007; Yehia et al., 2009). Samples 
of 5 ml were withdrawn at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 
16, 20 and 24 h time intervals and replaced with an equal 
volume of medium. The dissolution study was performed 
in triplicate. The concentration of dissolved ketoprofen 
was assayed by HPLC. The chromatographic conditions, 
adapted from a published method (Özlü et al., 2005) and 
used in a previous study (Hales et al., 2015), were: Agilent 
HPLC system (Agilent 1100 series, Agilent Technologies, 
SUA) equipped with a UV/Vis detector; stationary 
phase: Phenomenex Gemini C18 column (100 mm x 3 
mm, 3 µm); mobile phase: acetonitrile:phosphoric acid 
TABLE II – Composition of the powder mixture for compression-
coating
Constituent mg/tablet %
Lactose monohydrate DC 190.30 86.50
HPMC K100M 22.00 10.00
Silicon dioxide 1.10 0.50
Magnesium stearate 2.20 1.00
Opadry II Orange 4.40 2.00
Total 220.00 100.00
TABLE III – Film-coating formula and working conditions
Film-coating formula
Constituent Constituent quantity (%)
Core Compression-coated tablets 87.5
Film layer Eudragit® L 30D-55 9.0
Triethyl citrate 1.0
Talc 2.5
Working conditions
Parameter Value
Batch size (g) 230
Nozzle diameter (mm) 0.8
Atomization pressure (atm) 2.6-2.8
Nozzle flow rate (g/min) 7
Inlet air temperature (°C) 35-40
Outlet air temperature (°C) 28-34
Pre-heating of the tablets (min) 10
Spraying duration (min) 40
Post-coating drying in coating pan (min) 10
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solution 0.1% (60:40), isocratic elution; flow: 1 mL/min; 
temperature: 22 oC; wavelength: 260 nm (UV); pressure: 
222 bars; retention time: 1.05 min; injection volume: 
10 µL.
In vivo drug availability testing
The purpose of this part of the study was to assess 
the in vivo absorbtion of ketoprofen from IR-tablets and 
CR-tablets, and compare the results obtained with the ones 
achieved in the in vitro release study.
Subjects
Six healthy, non-smoking, caucasian volunteers 
aged between 28 and 33 years were enrolled in the study. 
The study was conducted according to the principles of the 
Declaration of Helsinki (1964) and its amendments and 
Good Clinical Practice rules. The clinical study protocol 
was reviewed and approved by the Ethics Committee of the 
University of Medicine and Pharmacy “Iuliu Hațieganu”, 
Cluj-Napoca, Romania. The volunteers were informed 
about possible risks and adverse effects of the drug, and 
written informed consent was obtained from each subject 
prior to enrollment. The health condition of each volunteer 
was assessed prior to the inclusion in the study.
In vivo pharmacokinetics study design
The study was designed as a cross-over, randomized 
study that consisted of two periods. During period 1, 
volunteers received a single oral dose of 103.2 mg 
ketoprofen from IR-tablets or CR-tablets (6 IR-tablets or 
6 CR-tablets). During period 2, the volunteers received 
the formulation they did not receive in period 1. Between 
the two periods, a 6-day wash-out period was introduced 
in order to allow the elimination of drug from the body. 
The drugs were administered in the morning, following an 
overnight fast (12 h), with at least 150 ml water. Following 
drug administration, the volunteers were allowed to drink 
water starting 2 h after dosing. Standardized meals were 
provided 3-h, 6-h and 10-h after drug administration.
Analysis of plasma samples
During each study period, venous blood (3 ml) 
was drawn into heparinized tubes before dosing (time 0) 
and at the following times: 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 
10, 12 and 24 h after drug administration. The separated 
plasma was stored at -20°C until analysis. Ketoprofen 
plasma concentrations were determined by a validated 
HPLC method with UV detection. The calibration curve 
for ketoprofen was linear between 153.2-19155.0 ng/ml. 
The chromatographic conditions were: Agilent HPLC 
system equipped with a UV/Vis detector; stationary 
phase: Zorbax SB-C18 column (100 mm x 3 mm, 3.5 µm); 
mobile phase: acetonitrile:trifluoracetic acid solution 
0.1% (45:55), isocratic elution; flow: 0.9 mL/min; 
temperature: 35 oC; wavelength: 257 nm (UV); injection 
volume: 4 µL.
Pharmacokinetic and statistical analysis 
Non-compartmental pharmacokinetic (PK) analysis 
was performed to determine the pharmacokinetic 
parameters of ketoprofen: maximum plasma concentration 
(Cmax, ng/ml), time to reach the peak plasma concentration 
(tmax, h), area under the concentration-time curve 
from time 0 to time of last quantifiable concentration 
(AUC0-t), area under the concentration-time curve from 
time 0 to infinity (AUC0-∞), elimination rate constant 
(kel), half-life (t½), mean residence time (MRT). The 
apparent cumulative absorption amount of ketoprofen 
was calculated by using deconvolution methodology. 
Analysis of variance (ANOVA) was used to compare the 
calculated pharmacokinetic parameters of ketoprofen for 
FIGURE 1 – Design of compression-coated tablets for colonic release (CR-tablets) and expected drug release behavior.
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the two periods, using general linear model procedures, in 
which the sources of variation were the formulation and 
the subject. All pharmacokinetic and statistical analyses 
were performed using Phoenix WinNonlin 6.3 (Pharsight, 
SUA) software.
RESULTS
The pharmacotechnical properties of granules, 
IR-tablets and compression-coated tablets
The ability of a powder to flow is evidenced by the 
determination of the compresibility index and Hausner 
ratio, which are measures of the propensity of a powder 
to be compressed and which allow an assessment of the 
relative importance of interparticulate interactions. Table 
IV shows the values of Hausner ratio, Carr’s index and 
particle size. Carr’s index (compresibility index) was 
in the range 11-15% (14.70%), indicating good flow. 
Similarly, Hausner ratio value was between 1.12-1.18 
(1.17), which indicated low interparticle friction. The 
size of the granules was 154.94 µm with a variation of 
46.60%, which showed a satisfactory homogeneity of 
the granules in terms of particle size. IR-tablets were 
analysed using standard pharmacotechnical methods for 
tablets in PhEur 8th edition and the pharmacotechnical 
results obtained are presented in Table IV. IR-tablets 
met the PhEur 8th edition requirements: they had good 
mass uniformity, short disintegration time, low friability, 
good hardness, good content uniformity and very good 
percentage of ketoprofen dissolved in 15 min. Also, the 
pharmacotechnical results obtained after compression-
coating of IR-tablets (cores) with HPMC K100M are 
presented in Table IV. According to the obtained results, 
compression-coated tablets presented good values for 
weight variation, friability, resistance to crushing, which 
were within the compendial limits.
In vitro drug release
Dissolution testing of colon delivery systems has 
usually been conducted in fluids simulating the pH in 
the gastric and intestinal environment, for transit times 
that the colon delivery system could encounter in vivo. 
Therefore, the release study of CR-tablets was performed 
in HCl 0.1 M (pH 1.2) for 2 h, then in phosphate buffer 
0.05 M (pH 6.8) for 3 h, followed by phosphate buffer 
0.05 M (pH 7.4) until the end of 24 h. The release profile 
of ketoprofen from CR-tablets, in dissolution media 
that simulated different portions of the digestive tract, is 
presented in Figure 2, together with the release profile 
of ketoprofen from IR-tablets. In CR-tablets, the enteric 
polymer, EL55, was able to prevent drug release in the 
simulated gastric fluid: ketoprofen was not detected in the 
first 2 h at pH 1.2. The efficiency of the enteric coating 
film was also observed while changing HCl medium 
with phosphate buffer (pH 6.8) inside the vessels; the 
tablets maintained their shape and the weight gain did 
not exceed 5% after being maintained in acidic medium 
for 2 h. Due to the fact that EL55 is soluble at pH>5.5 
(in the upper gastrointestinal tract), ketoprofen could 
have been released after polymer’s dissolution, but the 
HPMC layer delayed additionally the drug release, the 
first concentration of ketoprofen being detected after 6 
TABLE IV – Characterization of granules, IR-tablets and compression-coated tablets
Characterization of 
granules
Flow properties Values
Hausner ratio 1.17
Carr’s index 14.70
Granules size (µm) 154.94
CV (%) 46.60
Characterization 
of IR-tablets and 
compression-coated 
tablets
Test n IR-tablets Compression-coated tablets
Weight variation (mg ± SD) 20 20.61±0.38 240.55±1.43
Disintegration time (s ± SD) 6 8.33±1.36 -
Friability (%) 6.5g 0.215 0.200
Hardness (Newton ± SD) 10 31.40±3.53 259.00±8.30
Uniformity of content (% ± SD) 10 93.89±1.33 -
Drug release in 15 min (%) 3 92.24 -
IR-tablets – mini-tablets with immediate release; CV – coefficient of variation; SD – standard deviation.
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h. Moreover, ketoprofen percentages were insignificant 
between 6 h and 8 h (2.1-4.3%), but they increased 
suddenly and reached the maximum after 12 h (85.2%). 
Ketoprofen release from IR-tablets in neutral medium 
(phosphate buffer, pH 6.8) occured fast, 92.24% 
ketoprofen being dissolved after 15 min.
Pharmacokinetic and statistical analysis
The mean plasma concentration-time profiles for 
ketoprofen following the administration of IR-tablets and 
CR-tablets are shown in Figure 3. The graph illustrates 
clearly the difference between the two formulations, the 
maximum plasma concentration was lower and the time 
to reach the peak plasma concentration was longer for 
CR-tablets, which demonstrates the fact that the release 
starts after a lag time, compared to the immediate release 
of IR-tablets.
The mean pharmacokinetic parameters of ketoprofen 
obtained after the administration of IR-tablets and CR-
tablets, as well as the statistical test results, are presented 
in Table V.
The statistical analysis of Cmax values obtained 
for the oral administration of 103.2 mg ketoprofen as 
two different formulations (IR-tablets and CR-tablets) 
showed significant differences between the mean values 
obtained for the two formulations. The highest maximum 
concentration was obtained for IR-tablets (9549.50 
± 2156.12 ng/mL). For CR-tablets, the maximum 
concentration obtained represented half of the one of IR-
tablets (4920.33 ± 1626.71 ng/mL). The statistical analysis 
of tmax values obtained for the oral administration of 103.2 
mg ketoprofen as IR-tablets and CR-tablets showed also 
FIGURE 2 – Ketopofen release from IR-tablets (n=3) – in 
phosphate buffer (pH 6.8) for 24 h – and CR-tablets (n=3), in 
HCl (pH 1.2) for 2 h, followed by phosphate buffer (pH 6.8) for 
3 h and phosphate buffer (pH 7.4) for the next 19 h. IR-tablets – 
mini-tablets with immediate release; CR-tablets – compression-
coated tablets for colonic release.
FIGURE 3 – Mean ± SD plasma concentration-time curves of ketoprofen following the administration of IR-tablets and CR-tablets 
(n=6). Inset: semi-logarithmic presentation. IR-tablets – mini-tablets with immediate release; CR-tablets – compression-coated 
tablets for colonic release.
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significant differences between the mean values obtained 
for both formulations. For IR-tablets, peak plasma 
concentration was achieved after 1.33 ± 0.88 h, which 
means that the drug release occurred immediately after 
administration and the absorption took place rapidly. After 
oral administration, CR-tablets reached peak concentration 
at 5.33 ± 1.63 h, which showed that the designed system 
was able to delay the drug release. Between the AUC0-∞ 
obtained after administration of IR-tablets (26730.15 ± 
9137.55 ng*h/mL) and the area under the curve obtained 
after administration of CR-tablets (22121.58 ± 7773.11 
ng*h/mL), there was no statistically significant difference. 
The parameters used to characterize the elimination of 
ketoprofen were the elimination rate constant, the half-life 
and the apparent clearance. The elimination rate constant 
of ketoprofen showed a value of 0.29 ± 0.11 h-1 for the 
CR-tablets compared to 0.37 ± 0.10 h-1 for the IR-tablets, 
indicating a lower elimination rate for the colonic release 
system, although the difference was not statistically 
significant (p>0.05). The mean half-life of ketoprofen 
was 2.64 ± 0.71 h for the CR-tablets compared to 1.99 ± 
0.52 h for the IR-tablets. The elimination of ketoprofen 
with similar rate (p>0.05) following the administration 
of the two formulations can also be observed from the 
comparison of clearance values: 4302.17 ± 1535.21 
ml/h for IR-tablets and 5187.93 ± 1927.48 ml/h for 
CR-tablets. MRT of ketoprofen in the body presented a 
highly significant difference (p<0.001) between the two 
formulations: 2.51 ± 0.61 h for the IR-tablets and 7.07 
± 1.35 h for the CR-tablets. Since MRT is dependent on 
the rate at which the drug will move through a person’s 
body, this difference indicates the fact that CR-tablets are 
a delayed release system.
In vitro-in vivo comparison
The apparent cumulative amount of ketoprofen 
absorbed following the administration of IR-tablets and 
CR-tablets to 6 healthy volunteers is presented in Figure 
4. The differences between the two formulations are the 
time to acquire the maximum quantity absorbed and the 
value of the maximum quantity absorbed. The average 
apparent cumulative amount of ketoprofen absorbed was 
100% for the IR-tablets, while for the CR-tablets the mean 
value was 83.94±15.74%.
These results can be compared to the ones obtained 
during the in vitro dissolution studies (Figure 2). In 
the case of IR-tablets, approximately all amount of 
TABLE V – Mean ± SD pharmacokinetic (PK) parameters of ketoprofen in 6 healthy volunteers following the administration of 
IR-tablets and CR-tablets, respectively
PK parameter 
(mean ± SD)
Formulation
p-value*, ANOVA
IR-tablets CR-tablets
Cmax (ng/mL) 9549.50 ± 2156.12 4920.33 ± 1626.71 0.0003
tmax (h) 1.33 ± 0.88 5.33 ± 1.63 0.0005
AUC0-t (ng*h/mL) 26301.22 ± 8978.19 22036.78 ± 7873.03 0.0788
AUC0-∞ (ng*h/mL) 26730.15 ± 9137.55 22121.58 ± 7773.11 0.0668
kel (1/h) 0.37 ± 0.10 0.29 ± 0.11 0.0720
t1/2 (h) 1.99 ± 0.52 2.64 ± 0.71 0.0720
Cl (mL/h) 4302.17 ± 1535.21 5187.93 ± 1927.48 0.0788
MRT (h) 2.51 ± 0.61 7.07 ± 1.35 0.0000
IR-tablets – mini-tablets with immediate release; CR-tablets – compression-coated tablets for colonic release; *Statistically 
significant when p < 0.05.
FIGURE 4 – Apparent cumulative amount of ketoprofen 
absorbed following the administration of IR-tablets and CR-
tablets (n=6). IR-tablets – mini-tablets with immediate release; 
CR-tablets – compression-coated tablets for colonic release.
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ketoprofen (92.23±1.60%) dissolved after 15 min, and 
then the percentage increased slightly within 3 h up to a 
maximum of 93.73±1.72%. Similarly, in the case of the 
in vivo study of the same formulation, the absorption of 
ketoprofen was significant after 30 min (53.70±29.24%) 
and the maximum amount absorbed was on average 
nearly 100%. The CR-tablets prevented the absorption of 
ketoprofen for 5 h during the in vitro dissolution study, 
the first detectable concentrations (starting with the 6 h 
sample) being small initially, increasing sharply only after 
10 h and reaching the maximum (85.16±1.73%) after 16 
h. The same system tested by the in vivo study was able 
to prevent the absorption for 3 h, then the concentrations 
increased significantly in the range of 4-8 h and reached a 
maximum (83.94±15.74%) after 24 h.
DISCUSSION
In the present study, in order to verify that the 
characteristics evaluated by pharmacotechnical and in 
vitro studies for the CR-tablets designed in this work may 
be confirmed by in vivo studies, the system was evaluated 
on human subjects. The first steps were to determine 
different pharmaceutical properties of granules and tablets 
to verify their compliance with pharmacopoeia standards. 
Granules presented good flow and had a satisfactory 
homogeneity in terms of particles size. IR-tablets were 
found uniform in weight variation, disintegration time, 
friability, hardness and drug content, and allowed 
ketoprofen’s almost complete dissolution in approximately 
15 min. Compression-coated tablets’ evaluation showed 
also uniformity of weight variation, friability and hardness.
The dissolution studies revealed that CR-tablets 
were able to provide chronopharmaceutical colon-
specific ketoprofen release. EL55 outer film prevented 
water penetration to the HPMC K100M inner coat during 
stomach transit, the film being intact after 2 h in acidic 
environment, but dissolving after placing the CR-tablets 
in alkaline pH. In alkaline medium, the hydrophilic 
inner coat started to absorb water and to form a porous 
structure, but the drug release did not start immediately 
after the enteric polymer’s dissolution due to the high 
viscosity of the swollen gel which was able to control 
the drug diffusion. Similar results were observed in 
a previous study, which evaluated the influence of 
different types and concentrations of HPMC and enteric 
polymers on ketoprofen’s release (Hales et al., 2015). 
The system succeeded not only to delay ketoprofen 
release in the stomach and small intestine, but also to 
release a significant amount of drug at the targeted colon 
site. Therefore, IR-tablets provided desirable attributes 
according to the dissolution study: 6 h lag time and 85.2% 
drug release. Other groups of researchers found similar 
results: Patel et al. (2016) coated ketoprofen core tablets 
using a mixture of Eudragit® S100 and Eudragit® L100 
and obtained compression-coated tablets with 4 h lag time 
and more than 80% drug release; Devi and Sharma (2015) 
prepared compression-coated ketoprofen tablets using 
amylose/ethyl cellulose mixture and observed that during 
5 h the system released less than 20% ketoprofen, but 
finally reached 76.31% drug release; Alencar et al. (2017) 
found that Eudragit® S100 coated pellets compressed into 
tablets were able to release less than 20% ketoprofen for 
4 h, but to allow the release of approximately 90% of the 
drug until the end of the dissolution study.
The pharmacokinetic evaluation showed clear 
differences between IR-tablets and CR-tablets. Cmax 
values were lower for CR-tablets compared to IR-tablets, 
which is common for colon drug delivery systems since 
the main functions of the large bowel are water and 
electrolytes absorption, deposit and elimination of faeces, 
and not absorption of drugs and nutrients. Also, the 
colonic contents become more viscous with progressive 
absorption of water during colon transit, which causes a 
reduced dissolution rate, slow diffusion of dissolved drug 
through the mucosa and therefore, low amount of drug 
absorbed (Challa, Vynala, Allam, 2011). These findings 
were similar to the ones observed with some indomethacin 
colon targeted double-film-coated mini-tablets (Tomuţă 
et al., 2010).
Also, the time needed to reach Cmax (tmax) was higher 
for CR-tablets (5.33 ± 1.63 h) than for IR-tablets (1.33 
± 0.88 h). Pišlar et al. (2015) found that the median of 
gastric emptying, small intestinal transit and colon arrival 
times of subjects where the first meal intake was at 4 h 
post-dose was 35, 215, and 254 min, respectively. Also, 
other papers stated that stomach transit time is usually 
less than 1 h in fasting state (Challa, Vynala, Allam, 
2011). Therefore, in the case of IR-tablets, the results 
indicate that the absorption started in the stomach, as the 
first plasma concentrations appeared after 15 min, and 
occurred mainly in the small intestine. For CR-tablets, 
the time to reach peak plasma concentration was around 
5 h, which means that drug release occurred mainly in 
the large intestine. CR-tablets did not release the drug for 
approximately 3 h, which means that ketoprofen was not 
released in the stomach, nor in the upper and middle parts 
of the small intestine. The delayed release was due to the 
EL55 film that prevented activation of the system in the 
stomach and, afterwards to the HPMC K100M 10% layer 
which eroded with a lag time of about 3 h. Similar studies 
that investigated pharmacokinetic parameters following 
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colon drug delivery systems administration to dogs 
showed similar tmax values: approximately 5 h for diltiazem 
hydrochloride and phenylpropanolamine hydrochloride 
enteric coated timed-release press-coated tablets (Fukui 
et al., 2000), 5.20 ± 1.10 h for metoprolol tartrate oral 
sustained-release drug delivery system (Nakamura, Nara, 
Akiyama, 2006) or 5.3 ± 0.9 h for 5-aminosalicylic acid 
pressure-controlled colon delivery capsules (Takaya et 
al., 1998). A pharmacokinetic study conducted on human 
volunteers showed also a similar tmax of 5.7 ± 1.92 h for 
indomethacin double-film-coated mini-tablets (Tomuţă 
et al., 2010).
Comparing the AUC0-∞ of IR-tablets (26730.15 ± 
9137.55 ng*h/mL) and CR-tablets (22121.58 ± 7773.11 
ng*h/mL), one could observe that the colonic release 
formulation had a relative bioavailability of approximately 
85% compared to the immediate release formulation, 
therefore it could be considered that the absorption of the 
two formulations was close in terms of quantity absorbed 
(less than 15% difference). Similar pharmacokinetic 
studies also found no clear difference in AUC between 
immediate and colonic release dosage forms (Ishibashi et 
al., 1999), whereas others observed low bioavailability and 
incomplete absorption from colonic drug delivery systems 
due to the reduced water content in the lower intestine 
which tended to decrease drug absorption (Tomuţă et al., 
2010).
The MRT value for CR-tablets was 7.07 ± 1.35 h, 
which was 2.8 times longer than that for IR-tablets (2.51 
± 0.61 h). The value of MRT ratio between CR-tablets and 
IR-tablets was similar to the MRT ratio obtained in other 
studies: 2.8 for colon-specific double-compression coated 
mini-tablets (Vemula, 2015).
The apparent cumulative amount of ketoprofen 
absorbed presented similar values in vitro-in vivo, both for 
the IR-tablets (92.2±1.5% versus 100%) and CR-tablets 
(85.16±1.73% versus 83.94±15.74%). The time necessary 
to reach the maximum quantity absorbed was similar in 
vitro-in vivo (15 min-1 h) in the case of IR-tablets. The lag 
time presented by CR-tablets both in vitro and in vivo (3-6 
h) can be correlated with the colon arrival time mentioned 
in the literature (3-4 h) (Pišlar et al., 2015). This means that 
the lag time corresponds to the transit time of the stomach 
and the small intestine and that the release of ketoprofen 
started in the last part of the ileum or in the colon, the 
majority of drug release happening in the colon. Other 
studies, which worked on establishing an in vitro-in vivo 
correlation, established the relationship between in vitro 
and in vivo parameters through a correlation coefficient r2 
(Vemula, 2015). However, of all the data obtained in this 
study, it can be observed that the developed colonic system 
using time-dependent and pH-dependent techniques 
managed to prevent release of ketoprofen in the stomach 
and small intestine and allowed releasing a significant 
amount in the colon.
CONCLUSION
Herein, a compression-coated and film-coated tablet 
system for colonic release was designed and successfully 
achieved the aims of accomplishing the colon-specific 
release of ketoprofen. The controlled release colon 
delivery system was developed by compression-coating 
with a time-dependent polymer (HPMC K100M) and film-
coating with a pH-dependent polymer (Eudragit® L 30D-
55). In vitro studies showed that the pharmaceutical system 
was able to prevent drug release in acidic medium (0.1M 
HCl solution, pH 1.2) for 2 h and also in neutral medium 
(phosphate buffer, pH 6.8) for another 3 h, the drug release 
starting after 6 h (in phosphate buffer, pH 7.4) and reaching 
a maximum in approximately 16 h. According to the 
data obtained for the in vivo pharmacokinetic study, the 
absorption of ketoprofen from compression-coated tablets 
for colonic release occured after a lag time of 3 h (meaning 
that the drug release started in the last part of the ileum or 
in the colon), and the maximum plasma concentration was 
reached after 5.33 h (meaning that the greatest part of the 
drug was released in the large intestine). In conclusion, 
this system is a suitable approach to acquire colon-specific 
drug release of ketoprofen.
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